10 Crohns Disease Clinical Trials in Atlanta, GA (2026)

Q: How do I join a clinical trial in Atlanta?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you.

Recruiting Crohns Disease Studies in Atlanta

NCT05781152Recruiting

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pai...

Atlanta, GAPHASE4900 participantsConnecticut Children's Medical Center

View Study Details

NCT06226883Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately...

Atlanta, GAPHASE2385 participantsMorphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

View Study Details

NCT06233461Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in...

Atlanta, GAPHASE2268 participantsTakeda

View Study Details

NCT06663332Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active C...

Atlanta, GAPHASE3196 participantsJanssen Research & Development, LLC

View Study Details

NCT04844606Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

Atlanta, GAPHASE3150 participantsEli Lilly and Company

View Study Details

NCT06537258Recruiting

Heart Rate Variability and Inflammatory Bowel Disease

The goals of this study are to test the effectiveness of a virtually delivered, group-based coping skills treatment program incorporating heart rate variability biofeedback to target autonomic dysfunc...

Atlanta, GANA128 participantsEmory University

View Study Details

NCT04779320Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedoliz...

Atlanta, GAPHASE3120 participantsTakeda

View Study Details

NCT05923073Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among partic...

Atlanta, GAPHASE3120 participantsJanssen Research & Development, LLC

View Study Details

NCT05509777Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety...

Atlanta, GAPHASE390 participantsEli Lilly and Company

View Study Details

NCT07483099Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults wi...

Atlanta, GAPHASE260 participantsEli Lilly and Company

View Study Details

About Crohns Disease Clinical Trials in Atlanta

Crohn's disease is a chronic inflammatory bowel disease that causes inflammation anywhere in the digestive tract, most commonly in the small intestine and colon. Symptoms include abdominal pain, diarrhea, fatigue, and weight loss. Treatment includes anti-inflammatory drugs, immunosuppressants, biologics, and surgery.

There are currently 10 crohns disease clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 2,417 participants. Research is being sponsored by Connecticut Children's Medical Center, Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), Takeda and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Crohns Disease Clinical Trials in Atlanta — FAQ

Are there crohns disease clinical trials in Atlanta?

Yes, there are 10 crohns disease clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What crohns disease treatments are being tested?

The 10 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for crohns disease.

Data updated July 16, 2026 from ClinicalTrials.gov